Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T. H., Hochhaus, A., Hughes, T. P., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,550

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Druker, B. J., Guilhot, F., O’Brien, S. G., Gathmann, I., Kantarjian, H. M., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,516

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Kantarjian, H., Sawyers, C. L., Hochhaus, A., Guilhot, F., Schiffer, C. A., Gambacorti-Passerini, C. B., Niederwieser, D. W., Resta, D. J., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,005

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., PAQUETTE, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,614

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan‐Jacob, S. W., Ray, A., Huntly, B. J. P., Fabbro, D., Fendrich, G., Hall–Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,509

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

O’Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,296

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Baccarani, M., Cortes, J. E., Pane, F., Niederwieser, D. W., Saglio, G. N., Apperley, J. F., Cervantes, F., Deininger, M. W., Gratwohl, A. A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,276

Drug resistance and combating drug resistance in cancer

Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,147

Taxanes in cancer treatment: Activity, chemoresistance and its overcoming

Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 406

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D. G. F., Réa, D., & le Coutre, P. (2014) · Blood · doi:10.1182/blood-2014-09-594432 · Cited by 283

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

Pagliarini, R. A., Shao, W., & Sellers, W. R. (2015) · EMBO Reports · doi:10.15252/embr.201439949 · Cited by 264

Resisting Resistance: Targeted Therapies in Lung Cancer

Lin, J. J., & Shaw, A. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.010 · Cited by 241

A protective effect after clearance of orthotopic rat hepatocellular carcinoma by nanosecond pulsed electric fields

Chen, R., Sain, N. M., Harlow, K. T., Chen, Y.-J., Shires, P. K., Heller, R. F., & Beebe, S. J. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.07.006 · Cited by 91

Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML

Valent, P., Hadzijusufovic, E., Hoermann, G., Füreder, W., Schernthaner, G.-H., Sperr, W. R., Kirchmair, R., & Wolf, D. G. F. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.05.008 · Cited by 73

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia

El‐Tanani, M., Nsairat, H., Matalka, I. I., Lee, Y. F., Rizzo, M., Aljabali, A. A. A., Mishra, V. K., Mishra, Y., Hromić‐Jahjefendić, A., & Tambuwala, M. M. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155161 · Cited by 62

Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options

Sundaram, D. N. M., Jiang, X., Brandwein, J. M., Valencia‐Serna, J., Remant, K. C. B., & Uludağ, H. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.007 · Cited by 61

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Hehlmann, R., Cortes, J. E., Zyczynski, T. M., Gambacorti-Passerini, C. B., Goldberg, S. L., Mauro, M. J., Michallet, M., Simonsson, B., Williams, L. A., Gajavelli, S., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25306 · Cited by 56

CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells

Zhao, Y., Masiello, D., McMillian, M., Nguyen, C., Wu, Y., Melendez, E., Smbatyan, G., Kida, A., He, Y. J., Teo, J.-L., et al. (2015) · Oncogene · doi:10.1038/onc.2015.438 · Cited by 52

Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase

Hoemberger, M., Pitsawong, W., & Kern, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919221117 · Cited by 50

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective

Russo, E., Spallarossa, A., Tasso, B., Villa, C., & Brullo, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126538 · Cited by 47

Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases**

Shekhar, M., Smith, Z., Seeliger, M. A., & Tiwary, P. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202200983 · Cited by 48

Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells

Baykal, S., Açıkgöz, E., Yavuz, A. S., Geyik, Ö. G., Ateş, H., Sezerman, O. U., Özsan, G. H., & Yüce, Z. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229104 · Cited by 44

Induction of Heme Oxygenase-1 by Na+-H+ Exchanger 1 Protein Plays a Crucial Role in Imatinib-resistant Chronic Myeloid Leukemia Cells

Ma, D., Fang, Q., Wang, P., Gao, R., Wu, W., Lu, T., Cao, L., Hu, X., & Wang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.626960 · Cited by 43

Drug Resistance and its Clinical Circumvention

Moscow, J. A., Cowan, K. H., & Sikic, B. I. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm063 · Cited by 43

Sensitization of Chemo-Resistant Human Chronic Myeloid Leukemia Stem-Like Cells to Hsp90 Inhibitor by SIRT1 Inhibition

Kim, H.-B., Lee, S.-H., Um, J., Kim, M., Hyun, S.-K., Gong, E. J., Oh, W. K., Kang, C., & Kim, S. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10896 · Cited by 42

Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.

Gleixner, K. V., Filik, Y., Berger, D., Schewzik, C., Stefanzl, G., Sadovnik, I., Degenfeld‐Schonburg, L., Eisenwort, G., Schneeweiss‐Gleixner, M., Byrgazov, K., et al. (2021) · PubMed Central · Cited by 38

Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer

Bueschbell, B., Caniceiro, A. B., Suzano, P. M. S., Machuqueiro, M., Rosário‐Ferreira, N., & Moreira, I. S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100811 · Cited by 38

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?

Losson, H., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2020) · Cancers · doi:10.3390/cancers12020318 · Cited by 36

Self-enhanced luminol-based electrochemiluminescent hydrogels: An ultrasensitive biosensing platform for fusion gene analysis coupled with target-initiated DNAzyme motor

Duan, Y., Song, Y., Fan, N., Yao, Y., Deng, S., Ding, S., Shen, B., & Yin, Q. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113784 · Cited by 30

Resveratrol induces apoptosis of leukemia cell line K562 by modulation of sphingosine kinase-1 pathway.

Tian, H., & Yu, Z. (2015) · PubMed Central · Cited by 29

Update on emerging treatments for chronic myeloid leukemia

Fava, C., Morotti, A., Dogliotti, I., Saglio, G. N., & Rege‐Cambrin, G. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1031217 · Cited by 27

Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells

Rattigan, K. M., Brabcová, Z., Sarnello, D., Zarou, M. M., Roy, K., Kwan, R. S.-Y., de Beauchamp, L., Dawson, A., Ianniciello, A., Khalaf, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40222-z · Cited by 28

Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival

Noel, B. M., Ouellette, S. B., Marholz, L., Dickey, D., Navis, C., Yang, T.-Y., Nguyen, V., Parker, S. J., Bernlohr, D., Sachs, Z., et al. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00028 · Cited by 24

Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia

Khajapeer, K. V., & Rajasekaran, B. (2015) · Leukemia Research and Treatment · doi:10.1155/2015/757694 · Cited by 25

MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy

Li, Y., Tang, J., Chen, X.-Y., Luo, B., Liang, G.-H., Qu, Q., & Lu, Z. (2020) · Human Cell · doi:10.1007/s13577-020-00367-1 · Cited by 24

Resveratrol induces apoptosis in K562 cells via the regulation of mitochondrial signaling pathways.

Wang, B., Liu, J., & Gong, Z. (2015) · PubMed · Cited by 22

Just caring: Assessing the ethical and economic costs of personalized medicine

Fleck, L. M. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.09.013 · Cited by 20

BIRC6 mediates imatinib resistance independently of Mcl-1

Okumu, D. O., East, M. P., Levine, M., Herring, L. E., Zhang, R. J., Gilbert, T. S. K., Litchfield, D. W., Zhang, Y., & Graves, L. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177871 · Cited by 20

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML

Schneeweiss‐Gleixner, M., Byrgazov, K., Stefanzl, G., Berger, D., Eisenwort, G., Lucini, C. B., Herndlhofer, S., Preuner, S., Obrová, K., Pušić, P., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.004 · Cited by 20

PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β

Fan, R.-F., Lu, Y., Fang, Z., Guo, X., Chen, Y., Xu, Y., Lei, Y.-M., Liu, K.-F., Lin, D.-J., Liu, L., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7215 · Cited by 19

CBP/Catenin antagonists: Targeting LSCs’ Achilles heel

Kim, Y., Gang, E., & Kahn, M. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.010 · Cited by 19

Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

McGarry, L. J., Chen, Y. J., Divino, V. M., Pokras, S., Taylor, C. R., Munakata, J., Nieset, C., Huang, H., Jabbour, E. J., & Malone, D. C. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120189 · Cited by 17

1,4-Naphthoquinone (CNN1) Induces Apoptosis through DNA Damage and Promotes Upregulation of H2AFX in Leukemia Multidrug Resistant Cell Line

Portilho, A. J. D. S., da Silva, E. L., Bezerra, E. C. A., Gomes, C. B. D. S. M. R., Ferreira, V. F., de Moraes, M. E. A., da Rocha, D. R., Burbano, R. M. R., Moreira-Nunes, C. A., & Montenegro, R. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158105 · Cited by 17

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation

Combes, F. P., Sy, S. K. B., Li, Y. F., Lorenzo, S., Dasgupta, K., Kapoor, S., Hoch, M., & Ho, Y. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01411-1 · Cited by 16

Characteristics ofBCR-ABLkinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance

Patkar, N. V., Ghodke, K., Joshi, S., Chaudhary, S., Mascerhenas, R., Dusseja, S., Mahadik, S., Gaware, S., Tembhare, P. R., Gujral, S., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1157868 · Cited by 16

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

Martínez‐López, J., Mustjoki, S. M., Porkka, K., Klisovic, R. B., Wolf, D. G. F., Busque, L., Hernández‐Boluda, J. C., Swanink, R., Martin‐Regueira, P., & Lipton, J. H. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1889536 · Cited by 15

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial

Yen, R., Grasedieck, S., Wu, A., Lin, H., Su, J., Rothe, K., Nakamoto, H., Forrest, D. L., Eaves, C. J., & Jiang, X. (2022) · Leukemia · doi:10.1038/s41375-022-01680-4 · Cited by 15

Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report

Wang, D., Shi, R. H., Wang, Q., & Li, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s164430 · Cited by 14

Analogs, formulations and derivatives of imatinib: a patent review

Musumeci, F., Schenone, S., Grossi, G., Brullo, C., & Sanna, M. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1089233 · Cited by 14

Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia

Knopf, K., Divino, V. M., McGarry, L. J., Chen, Y. J., Pokras, S., Munakata, J., Taylor, C. R., Ng, D., Nieset, C., & Huang, H. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.647 · Cited by 13

The Role of Pharmacogenomics in Individualized Medicine

zu Schwabedissen, H. E. M. (2015) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-319-11719-5_7 · Cited by 12

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review

Morozova, Е. V., Vlasova, Y. Y., Pryanishnikova, M. V., Lepik, K. V., & Afanasyev, B. V. (2015) · Biomarker Insights · doi:10.4137/bmi.s22438 · Cited by 12

Multidrug resistance in chronic myeloid leukemia

Yazıcı, M. Ü., Kiraz, Y., Kacı, F. N., Özcan, M. A., & Baran, Y. (2014) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1405-21 · Cited by 11

ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells

Wu, J., Wei, B., Wang, Q., Ding, Y., Deng, Z.-K., Lü, X., & Li, Y. (2016) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-016-0725-x · Cited by 11

Should Vascular Effects of Newer Treatments be Addressed More Completely?

Yang, E. H., Watson, K. E., & Herrmann, J. (2015) · Future Oncology · doi:10.2217/fon.15.119 · Cited by 11

Verbascoside potentiates the effect of tyrosine kinase inhibitors on the induction of apoptosis and oxidative stress via the Abl-mediated MAPK signalling pathway in chronic myeloid leukaemia

Çağlıyan, G. A., Çört, A., Kılıç-Toprak, E., & Altıntaş, F. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11441 · Cited by 10

EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins

Li, L., Xu, N., Zhang, J., Xu, L., Zhou, X., Huang, B.-T., Li, Y., & Liu, X. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.14989 · Cited by 10

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX

Wu, J., Wei, B., Shi, Y., Lü, X., Ding, Y., Wang, C., & Li, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10539 · Cited by 10

Electronic and structural study of T315I mutated form in DFG-out conformation of BCR-ABL inhibitors

Pereira, W. A., Nascimento, É. C. M., & Martins, J. B. L. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1935320 · Cited by 9

Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories

Khair, H. E., Moha, B. A., Nour, B. Y., & Waggia, H. A. (2022) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2022.175.181 · Cited by 9

Colorimetric determination of BCR/ABL fusion genes using a nanocomposite consisting of Au@Pt nanoparticles covered with a PAMAM dendrimer and acting as a peroxidase mimic

Yang, P., Shen, H., Tang, S., Huang, Z., Hao, Y., Luo, Z., Zhou, F., Wang, T., & Feng, W. (2018) · Microchimica Acta · doi:10.1007/s00604-018-2940-1 · Cited by 9

Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population

Breccia, M., Rossi, A. R., Giai, V., Martino, B., Fava, C., Annunziata, M., Abruzzese, E., Binotto, G., Baratè, C., Nardozza, A. P., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70101 · Cited by 8

The importance of personalized medicine in chronic myeloid leukemia management: a narrative review

Zaker, E., Nouri, N., Sorkhizadeh, S., Ghasemirad, H., Hajijafari, A. H., & Zare, F. (2023) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-023-00411-3 · Cited by 8

Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells

Özel, B., Kıpçak, S., Avcı, Ç. B., Gündüz, C., Saydam, G., Aktan, Ç., & Günel, N. S. (2022) · Medical Oncology · doi:10.1007/s12032-021-01643-2 · Cited by 8

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells

Yang, Y., Liu, X., Xiao, F., Xue, S., Xu, Q., Yin, Y., Sun, H., Xu, J., Wang, H., Zhang, Q., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117573 · Cited by 7

The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program

Sacha, T., Szczepanek, E., Dumnicka, P., Góra‐Tybor, J., Niesiobędzka‐Krężel, J., Prejzner, W., Wasilewska, E. M., Kloczko, J. S., Ciepłuch, H., Makowska, W., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.012 · Cited by 7

The regulation of bcr-abl in hypoxia is through the mTOR pathway

Clapper, E., Trapani, G. D., & Tonissen, K. F. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1849679 · Cited by 7

Systematic optimization of reverse phase ultra‐high‐performance liquid chromatography method for quantification of nilotinib and its related substances in bulk drug and pharmaceutical formulation using quality by design approach

Prasad, S. K., & Divekar, K. (2024) · Separation Science Plus · doi:10.1002/sscp.202300185 · Cited by 6

High-throughput formulation of reproducible 3D cancer microenvironments for drug testing in myeloid leukemia

Rudzińska, M., Turos-Korgul, L., Mukherjee, D., Podszywalow‐Bartnicka, P., Piwocka, K., & Guzowski, J. (2024) · Biofabrication · doi:10.1088/1758-5090/ad998d · Cited by 6

Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia

Machado‐Alba, J. E., & Machado‐Duque, M. E. (2017) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-017-0484-9 · Cited by 6

Therapeutic Responses of Imatinib and Nilotinib among CML Patients in Hasan Sadikin Hospital Bandung

Sumantri, A. F., Oehadian, A., Wijaya, I., Vidyaniati, P., & Rahmaniati, R. (2019) · Indonesian Journal of Cancer · doi:10.33371/ijoc.v12i3.615 · Cited by 6

Rational Approach to New Chemical Entities with Antiproliferative Activity on Ab1 Tyrosine Kinase Encoded by the BCR-ABL Gene: An Hierarchical Biochemoinformatics Analysis

Sanches, V. H. S., Lobato, C. C., Silva, L. B., dos Santos, I. V. F., Barros, E. D. S., Maciel, A. D. A., Ferreira, E. F. B., da Costa, K. S., Espejo-Román, J. M., Rosa, J. M. C., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17111491 · Cited by 5

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate

Mariam, I. S., Norhidayah, R., Zulaikha, A. B., Yunus, N. M., Hassan, R., Ghazali, A. K., Sarina, S., Azlan, H., & Ankathil, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.720845 · Cited by 5

Anticancer Activity and Molecular Mechanism of Momordica cochinchinensis Seed Extract in Chronic Myeloid Leukemia Cells

Ai, Z., Ma, C., Wan, R., Yin, J., Li, G., Li, Y., & Chen, L. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.2014904 · Cited by 5

Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches

Preuner, S., Barna, A., Frommlet, F., Czurda, S., Byrgazov, K., Alikian, M., Poláková, K. M., Sacha, T., Richter, J., Lion, T., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050642 · Cited by 5

The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance

Shirbhate, E., Singh, V. P., Kore, R., Vishwakarma, S., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266284527240118041129 · Cited by 4

Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review

Zhang, Y. L., Chen, W., Pathak, A., Yang, Y., Yang, D., & Zhai, Y. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0032 · Cited by 4

Agent-Based Models Help Interpret Patterns of Clinical Drug Resistance by Contextualizing Competition Between Distinct Drug Failure Modes

Leighow, S. M., Landry, B. D., Lee, M. J., Peyton, S. R., & Pritchard, J. R. (2022) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-022-00748-6 · Cited by 5

p38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia

Bhat, M., Narasimhan, M., Shelar, A., Patwardhan, R., Sandur, S. K., & Govekar, R. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114870 · Cited by 3

Differential expression ofSHP-1in chronic myeloid leukemia

Kaeda, J., Neuman, D., Bonecker, S. T., Mills, K., Oberender, C., Amini, L., Ringel, F., Serra, A., Schwarz, M., Dörken, B., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.969258 · Cited by 3

Electronic and Structural Insights of BCR-ABL Inhibitors Under LMC Treatment Perspective

Nascimento, É. C. M., Nascimento, L. D. A., Benicio, L. F. M. A., Alcântara, J. L. L., Pereira, W. A., & Martins, J. B. L. (2022) · Engineering materials · doi:10.1007/978-3-031-07622-0_15 · Cited by 3

Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia

Nekoohesh, L., Rostami, S., Nikbakht, M., Mohammadi, S., Babakhani, D., Alimoghaddam, K., Ghahremani, M. H., & Chahardouli, B. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.605 · Cited by 3

Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia

Sarlon-Bartoli, G., Michel, Q., Sarlon, E., Carcopino-Tusoli, M., Suchon, P., Soler, R. J., Bartoli, M. A., Brunet, D., Morange, P., & Charbonnier, A. (2021) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2021.02.002 · Cited by 3

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients – worldwide battlefield

Dvořák, P., Lysák, D., & Vokurka, S. (2015) · Neoplasma · doi:10.4149/neo_2015_021 · Cited by 2

Precision Deuteration in Search of Anticancer Agents: Approaches to Cancer Drug Discovery

Mourya, A., & Prajapati, N. K. (2023) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0031 · Cited by 2

Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia

Breccia, M., Molica, M., & Alimena, G. (2015) · Clinical Investigation · doi:10.4155/cli.14.129 · Cited by 2

Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?

Eşkazan, A. E. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1571202 · Cited by 2

Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias

Alekrish, Y., Alotaibi, S., Iqbal, Z., & Aleem, A. (2025) · Cureus · doi:10.7759/cureus.86322 · Cited by 1

Targeting Musashi-2 to counteract senescence and resistance in chronic myeloid leukemia: enhancing the efficacy of imatinib therapy

Arif, K., Yousaf, M., & Khan, D. (2025) · BMC Cancer · doi:10.1186/s12885-025-15214-5 · Cited by 1

[Imatinib mesylate for chronic myeloid leukemia: in patients with initial treatment versus those with Recombinant Human IFN-α2b treatment failure].

Jiang, J., Xu, W., & Qian, W. (2015) · PubMed Central · doi:10.3785/j.issn.1008-9292.2015.03.010 · Cited by 1

Głęboka odpowiedź molekularna po podaniu dazatynibu w 3. linii terapii u chorego na przewlekłą białaczkę szpikową w fazie przewlekłej

Lewandowska, M., Gniot, M., Ratajczak, B., Jarmuż‐Szymczak, M., & Lewandowski, K. (2015) · Hematologia · doi:10.5603/hem.2015.0031 · Cited by 1

Skuteczne leczenie ratunkowe inhibitorami kinaz tyrozynowych chorego na B-komórkową ostrą białaczkę limfoblastyczną Filadelfia-dodatnią

Seferyńska, I., Ejduk, A., Solarska, I., & Warzocha, K. (2018) · Hematologia · doi:10.5603/hem.2018.0005 · Cited by 1

PROGNOSTIC VALUE OF CYP3A5 AND hOCT1 POLYMORPHIC GENE VARIANTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE REPUBLIC OF BASHKORTOSTAN

Сафуанова, Г. Ш., Рябчикова, Н. Р., Хуснутдинова, Э. К., Karimov, D. O., & Minniakhmetov, I. R. (2019) · Гематология и трансфузиология · doi:10.35754/0234-5730-2019-64-2-165-174 · Cited by 1

A Single Center Study of Prescribing and Treatment Outcomes of Patients with Chronic Myeloid Leukemia

Nekoohesh, L., Ghahremani, M. H., Rostami, S., Nikbakht, M., Nekoohesh, L., Naemi, R., Mohammadi, S., Nejad, L. G., Mousavi, S. A., Vaezi, M., et al. (2020) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v14i1.2324 · Cited by 1

Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases**

Shekhar, M., Smith, Z., Seeliger, M. A., & Tiwary, P. (2022) · Angewandte Chemie · doi:10.1002/ange.202200983 · Cited by 2

Evaluation of 389nm UV-LED to Induce Apoptosis in Leukemia Cells for Develop Implant Photonics-Device

Inada, S. A. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.19.003379 · Cited by 1

GOLDEN fusion: a graph-oriented learning with domain-embedding network fusion for generating super gene sets in functional genomics

Li, Q., Nichols, C., Welner, R. S., Chen, J. Y., Ku, W.-S., & Yue, Z. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag244

Understanding life and death decisions in human leukaemias

MacEwan, D. J., Barrera, L. N., Keadsanti, S., Rushworth, S. A., Shah, N., Yuan, T., & Zaitseva, L. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140127

Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

Eşkazan, A. E. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1295145

Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq

Rahem, R. M., Abuhmood, A. A., & Hussein, L. (2017) · Karbala International Journal of Modern Science · doi:10.1016/j.kijoms.2017.08.004

BCR/ABL1 KINASE DOMAIN MUTATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH SECONDARY RESISTANCE TO THE IMATINIB THERAPY

Dmytrenko, I. V., Мінченко, Ж. М., & Dyagil, I. (2018) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2018-1-2-143-249-254

Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience

Saleem, U., Hafeez, T., Raza, S. A., Tahir, M., Khalid, F., & Islam, M. K. (2020) · Cureus · doi:10.7759/cureus.7826

Study on Mutation Resistance to Imatinib in Chronic Myeloid Leukemia Patients from West India

Darji, A., & Bharadia, P. D. (2021) · Science Journal of Analytical Chemistry · doi:10.11648/j.sjac.20210901.11

Pre-clinical evaluation of targeting autophagy for the treatment of Oral Squamous Cell Carcinoma

Magnano, S. (2021) · Arrow@dit (Dublin Institute of Technology)

The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia

Clapper, E., Trapani, G. D., & Tonissen, K. F. (2021) · Hemato · doi:10.3390/hemato2020014

Biomarkers in Cancer Survival and Drug Resistance

Ikram, M., & Uddin, Z. (2022) · Springer eBooks · doi:10.1007/978-981-16-5759-7_7

Phenotypically plastic drug‐resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model

Baykal, S., Yüce, Z., & Özhan, G. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70105

Mechanisms of resistance to BCR–ABL kinase inhibitors

Diamond, J., & Melo, J. V. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.546920 · Cited by 55

Analysis of the Molecular Determinants of the Response of Chronic Myelogenous Leukaemia to Tyrosine Kinase Inhibitors

Labussière, H., Hayette, S., & Nicolini, F. E. (2007) · Current Pharmacogenomics · doi:10.2174/157016007781669231

Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia

Balabanov, S., Braig, M., & Brümmendorf, T. H. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.03.003 · Cited by 78

Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia

Marfè, G., & Stefano, C. (2014) · Current Drug Discovery Technologies · doi:10.2174/1570163811666140212111508 · Cited by 4

Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance

Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204